[Retracted] Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia

Table 4

Cell cycle distribution of the treatment groups on SUP-B15 and NCI-BL 2171 cells.

Treatment group	G0/G1 (%)		S (%)		G2/M (%)
	SUP-B15	NCI-BL 2171	SUP-B15	NCI-BL 2171	SUP-B15	NCI-BL 2171
Anti-miR-146a	66.59	63.37	6.05	17.49	27.36	19.14
Anti-miR-146a & IC50 dose of prednisolone	74.23	52.36	3.09	26.18	22.68	21.46
Anti-miR-155	58.16	45.52	6.49	36.9	35.36	17.59
Anti-miR-155 & IC50 dose of prednisolone	75.30	73.29	1.22	4.82	23.48	21.89
Anti-miR-181a	74.85	67.87	6.44	15.9	18.71	16.23
Anti-miR-181a & IC50 dose of prednisolone	75.58	51.32	2.64	22.86	21.78	25.82
Anti-let-7e	58.85	52.67	11.96	25.35	29.19	21.98
Anti-let-7e & IC50 dose of prednisolone	49.68	38.14	0.65	29.66	49.68	32.20
Anti-miR-146a + anti-miR-155 + anti-miR-181a + anti-let-7e combination	66.50	72.90	4.40	9.92	29.10	17.18
Anti-miR-146a + anti-miR-155 + anti-miR-181a + anti-let-7e combination & IC50 dose of prednisolone	75.26	47.87	1.37	25.2	23.37	26.93
IC50 dose of prednisolone	55.21	55.67	0.47	19.15	44.31	25.18
Control	56.03	40.64	14.93	21.93	29.04	37.43

Fisher’s exact test, <0.05 and <0.01.